Benign and time-limited visual disturbances (flashbacks) in recent abstinent high-potency heavy cannabis smokers: A case series study

Israel Journal of Psychiatry and Related Sciences

Volumn 48, Issue 1, 2011, Pages 25-29

  Lerner, Arturo G ^a,b   Goodman, Craig ^a   Rudinski, Dmitri ^a   Bleich, Avi ^a,b  

^a LEV HASHARON MENTAL HEALTH CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79954456914     PISSN: 03337308     EISSN: 26172402     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Rudgley R. The encyclopedia of psychoactive substances. New York: St. Martin's Press, 1999.
2. Ott J. Entheogens II: On entheology and entheobotany. J Psychoactive Drugs 1996; 28: 205-209.
3. Strassman RJ. Human psychopharmacology of LSD, dimethyltryptamine and related compounds. A Symposium of the Swiss Academy of Medical Sciences Lugano-Agno 1993. In: Pletscher A, Ladewig D, editors. 50 years of LSD: Current status and perspectives of hallucinogens. New York: Parthenon Publishing Group, 1994.
4. Inaba DS, Cohen WE, Holstein ME. Uppers owners, all arounders. Physical and mental effects of psychoactive drugs. Third ed. Ashland, Oregon: CNS Publications, Inc., 1997.
5. Abraham HD, Aldridge AM. Adverse consequences of lysergic acid diethylamide. Addiction 1993; 88:1327-1334.
6. Abraham HD, Aldridge AM, Gogia P. The psychopharmacology of hallucinogens. Neuropsychopharmacology 1996;14:285-298.
7. Abraham HD. Visual phenomenology of the LSD flashbacks. Arch Gen Psychiatry 1983; 40:884-889.
8. Abraham HD. Hallucinogen related disorders. In Sadock BJ, Sadock VA, editors. Kaplan & Sadock's Comprehensive textbook of Psychiatry, Vol. 1, 7th edition. Philadelphia: Lippincott Williams & Wilkins, 2000.
9. Lerner AG, Gelkopf M, Oyffe I, Finkel B, Katz S, Sigal M, Weizman A. LSD-induced hallucinogen persisting perception disorder (HPPD) treatment with clonidine: An open pilot study. Int Clin Psychopharmacol 2000, 18:35-37.
10. Lerner AG, Gelkopf M, Skladman I, Oyffe I, Finkel B, Sigal M, Weizman A. Flashback and hallucinogen persisting perception disorder: Clinical aspects and pharmacological treatment approach. Isr J Psychiatry Rel Sci 2002;39:92-99.
11. Lerner AG, Gelkopf M, Skalman I, Rudinski R, Nachshon H, Bleich A. Clonazepam treatment of LSD-induced hallucination persisting perception disorder with anxiety features. Int Clin Psychopharmacol 2003;18:101-105.
12. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, D.C.: American Psychiatric Association, 2000.
13. Tennant FS, Groesbeck CJ. Psychiatric effects of hashish. Arch Gen Psychiatry 1972;27: 133-136.
14. Stanton MD, Mintz J, Franklin RM. Drug flashbacks II: Some additional findings. Int J Addict 1976;11: 53-69.
15. Tunving K. Psychiatric effects of cannabis use. Acta Psychiatr Scand 1985;72: 209-217.
16. Shufman E, Lerner AG, Witztum E. Depersonalization after cannabis usage. Harefuah 2005;144: 249-251 (in Hebrew).
17. Szymanski HV. Prolonged depersonalization after marijuana use. Am J Psychiatry 1981; 138:231-233.
18. Annis AM, Smart RG. Adverse reactions and recurrences from marijuana use. Br J Addiction 1973;68: 315-319.
19. Stanton MD, Bardoni A. Drug flashbacks: Reported frequency in a military population. Am J Psychiatry 1972;129: 751-755.
20. Isbell H, Gorodetzsky CW, Jasinski DR. Effects of delta-9-transtetrahydrocannabinol in man. Psychopharmacologia 1967; 11: 184-188.
21. Keeler MH, Reifler CB, Liptzin MB. Spontaneous recurrence of marihuana effect. Am J Psychiatry 1968; 125: 384-386
22. Ashton H. Pharmacology and effects of cannabis: A brief review. Br J Psychiatry 2001;178: 101-106.
23. Cone EJ, Welch P, Lange WR. Clonidine partially blocks the physiological effects but not the subjective effects produced by smoking marijuana in male humans subject. Pharmacol Biochem Behav 1988; 29: 649-652.
24. Sander-Bush E, Burris KD, Knoth K. Lysergic acid diethylamide and 2,5-dimethoxy-4-mathylamphetamine are partial agonists at serotonin receptors linked to phosphoinositide hydrolysis. J Pharmacol Exp Ther 1988; 246:924-928.
25. Russo EB, Burnett A, Hall B. Parker KK. Agonist properties of cannabidiol at 5-HT 1A receptors. Neurochem Res 2005; 30: 1037-1043.
26. Hill MN, Sun JC, Tse MT, Gorzalka BB. Altered responsiveness of serotonin receptor subtypes following long term cannabinoid treatment. Int J Neuropsychopharmacol 2006;9: 277-286.
27. Sierra M. Depersonalization disorder: Pharmacological approaches. Expert Rev Neurother 2008;8: 19-16.
28. Mathew RJ, Wilson WH, Humphreys D. Lowe JV, Weithe KE. Depersonalization after marijuana smoking. Biol Psychiatry 1993;33:431-441.
29. Young CR. Sertraline treatment of hallucinogen persisting perception disorder. J Clin Psychiatry 1997;58:85.
30. Garrat J, Alreja M, Aghajanian GK. LSD has high efficacy relative to serotonin in enhancing the cationic current Ih: Intracellular studies in rat facial motorneurons. Synapse 1993;13:123-134.
31. Lauterbach EC, Abdelhamid A, Annandale JB. Posthallucinogenlike visual illusions (palinopsia) with risperidone in a patient without previous hallucinogen exposure: Possible relation to serotonin 5HT2a receptor blockade. Pharmacopsychiatry 2000;33:38-41.
32. Schwartz K. Nefazodone and visual side effects. Am J Psychiatry 1997; 154:1038.
33. Hughes MS, Lessell S. Trazodone-induced palinopsia. Arch Ophthal 1990;108:399-400.
34. Lerner AG, Shufman E, Kodesh A, Kretzmer G, Sigal M. LSD-induced hallucinogen persisting perception disorder with depressive features treatment with reboxetine. Isr J Psychiatry Relat Sci 2002; 39: 100-103.
35. Lucca A, Serreti A, Smeraldi E. Effects of reboxetine augmentation in SSRI resistant patients. Hum Psychopharmacol Clin Exp 2000; 15: 143-145.
36. Stein MB, Uhde TW. Depersonalization disorder: Effects of caffeine and response to pharmacotherapy. Biol Psychiatry 1989;26: 315-320.
37. Hewlett WA, Vinogradov S, Agras WS. Clomipramine, clonazepam, and clonidine treatment of obsessive compulsive disorder. J Clin Psychopharmocol 1992;12: 420-430.
38. Leweke FM, Schneider U, Thies M, Munt TF, Emrich HM. Effects of synthetic delta 9-tetrahydrocannabinol on binocular depth inversion of natural and artificial objects in man. Psychopharmacology 1999; 142: 230-235.
39. Leweke FM, Schneider U, Radwan M, Schmidt E, Emrich HM. Different effects of nabilone and cannabidiol on binocular depth inversion in man. Pharmacology, Biochemistry and Behavior 2000; 66: 175-181.
40. World Health Organization. Program on substance abuse. Cannabis: A health perspective and research agenda. Geneva: WHO, 1997.
41. Gold MS. Marihuana. In: Miller NS, editor. Comprehensive handbook of alcohol and drug addiction. New York: Marcel Decker, 1991.